Researchers found that a specific class of diabetes medications, known as sodium-glucose cotransporter 2 inhibitors (SGLT2i), may significantly benefit older adults with type 2 diabetes. A recent study involving nearly 8,500 individuals aged 75 and older revealed that those who started taking SGLT2i had a lower risk of dying from any cause and a reduced chance of developing severe kidney issues compared to those who began treatment with dipeptidyl peptidase-4 inhibitors (DPP-4i).

This finding is particularly important for older adults looking to maintain their health as they age. Lower all-cause mortality means that SGLT2i could help you live longer, while a reduced risk of end-stage renal disease suggests better kidney health. For seniors managing diabetes, these medications could be a key part of a strategy to enhance overall well-being, potentially leading to a healthier, more active lifestyle.

However, it’s essential to approach these results with caution. The study, published in the journal Ageing, analyzed data from administrative claims and health examinations, which means it reflects real-world outcomes but is not a randomized controlled trial. While the evidence shows promising benefits of SGLT2i for older adults, there were also indications of an increased risk of stroke among users of this medication, which requires further investigation. Therefore, while SGLT2i may offer significant advantages for older adults with diabetes, it’s crucial to consult healthcare providers to weigh the benefits and risks tailored to individual health needs.